Member Info for Basser1

Https://x.com/physiomics/status/1697239274629030376?s=12

I recall Merk being very interested in using SRA737 in Cancer combination therapies.

Https://www.sickeconomics.com/2019/01/25/3-signs-biotech-acquired/

Regarding HBDs find on SDC-01 f-first on the list of Jak inhibitors expected to have a significant impact of the Jak inhibitor market in the coming years. What a bargain price Sareum is at this level. Even now only just above 2p on pre consolidation.

Hi Hot. Appreciate your post but let’s be silent a wait patiently. We do not know when so no point in speculating.

Cheers

Some chunky buys today. If it continues then we will start to have some momentum. The recording of sells as buys is a disgrace and has been going on for some considerable time now. Really should be something for the Financial Conducts Authority to investigate. But don’t hold your breath.

Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959504/#B22-ijms-24-03391

Paper published in Feb23 with mentions of SAR 20347 at 4.5 and 5. Discussion.

Like to think it’s inside knowledge from Boston!

Given the published price recommendation by Peel Hunt might there be some big buys before close? So small volume of just 84,000 shares does not warrant this drop. Aim in the main just a short term gambling machine.

So Sareum is now a clinical stage Company and Tim is at the Bio Conference in Boston. Would be nice to know whether there has be a meeting ( or meetings) set up in advance. Timing is intriguing.

TYK2 is all the rage at this time. To have small molecules like this in a capsule oral format is very exciting indeed. Not long know I think.

Sareum’s policy is to licence at late pre clinical or early clinical stages. They are now in the early clinical stage. It was at this time that SRA737 was licensed as pharmas like to take control at this stage. We are now ripe for licensing or a takeover. iThis is great news. Not long to wait now in my view. GLA

I tend to disagree. Sareum approach is deals done at late pre clinical into early clinical. Besides which I would have thought that Peel Hunt clients want results sooner rather than later - certainly not in 2 years time. Anyway we are all guessing, so nobody should be swayed one way or the other by comments on this board.

Great news re start of clinical trials.

Never thought I would see a price of 2.6p post clinical.

Awful what’s being done with the manipulation and deception relating to the share price to ensure that the rich get even richer. But I guess that’s the way of the World now. Sad.

And Tim Mitchell travels to the Bio International Convention - Boston USA on the 5th June. Over 14,000 attendees with a particular focus on Partnership opportunities. Interesting.

Yep - it certainly isn’t subtle.

Ahfam - I still can’t see how a small bio like Sareum can licence to a major pharma especially with 1802 following on. 1801 and 1802 look too valuable to go to smaller bios and in any case might lead to a Sierra scenario which we would not want repeated. Far easier for large pharmas to buy out the company. Happy to see views to the contrary showing how licensing might work in the current climate.

Laz - I think we still underestimate the attractiveness of the capsule format that 1801 ( and I assume 1802) can give us a further advantage ( provided the trial results are good).!

Personally cannot see a small bio like Sareum doing a licence deal with a major pharma. That scenario does not fit very well in the current climate. Seems lots of activity going on behind the scenes. My bet would be on a takeover and the odds for that happening would be fairly short in my view.

That Tim Mitchell is attending the Bio International Convention in Boston 5-8th of June - around same time as clinical trials commence.

Dan - Can you clarify on why Dr Jane Doe is a dubious name? Lol